Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy

Genome engineering using the CRISPR-Cas9 system

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133 · see citing works

RNA-Guided Human Genome Engineering via Cas9

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210 · see citing works

The new frontier of genome engineering with CRISPR-Cas9

Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · see citing works

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · see citing works

Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes

Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P., Dickman, M. J., Makarova, K. S., Koonin, E. V., & John van der, O. O. S. T. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,593 · see citing works

CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III

Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563 · see citing works

Evolution and classification of the CRISPR–Cas systems

Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2577 · Cited by 2,512 · see citing works

A Robust CRISPR/Cas9 System for Convenient, High-Efficiency Multiplex Genome Editing in Monocot and Dicot Plants

Ma, X., Zhang, Q., Zhu, Q., Liu, W., Chen, Y., Qiu, R., Wang, B., Yang, Z., Li, H., Lin, Y., et al. (2015) · Molecular Plant · doi:10.1016/j.molp.2015.04.007 · Cited by 2,369 · see citing works

CRISPR–Cas9 Structures and Mechanisms

Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029 · see citing works

CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling

Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001 · see citing works

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962 · cited 2× · see citing works

Engineered CRISPR-Cas9 nucleases with altered PAM specificities

Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624 · see citing works

CRISPR-engineered T cells in patients with refractory cancer

Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · see citing works

The next generation of CRISPR–Cas technologies and applications

Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459 · see citing works

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338 · see citing works

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273 · see citing works

Delivering CRISPR: a review of the challenges and approaches

Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185 · see citing works

Targeting HER2-positive breast cancer: advances and future directions

Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160 · see citing works

Efficient genome editing in plants using a CRISPR/Cas system

Feng, Z., Zhang, B., Ding, W., Liu, X., Yang, D., Wei, P., Cao, F., Zhu, S., Zhang, F., Mao, Y., et al. (2013) · Cell Research · doi:10.1038/cr.2013.114 · Cited by 1,070 · see citing works

Diversity and evolution of class 2 CRISPR–Cas systems

Shmakov, S., Smargon, A. A., Scott, D. A., Cox, D. B. T., Pyzocha, N., Yan, W. X., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.184 · Cited by 1,056 · see citing works

Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials

Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986 · see citing works

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978 · see citing works

Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition

Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942 · see citing works

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · see citing works

NR4A transcription factors limit CAR T cell function in solid tumours

Chen, J., López-Moyado, I. F., Seo, H., Lio, C.-W. J., Hempleman, L. J., Sekiya, T., Yoshimura, A., Scott-Browne, J. P., & Rao, A. (2019) · Nature · doi:10.1038/s41586-019-0985-x · Cited by 874 · see citing works

Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects

Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J.-Y., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 827 · see citing works

RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System

Xie, K., & Yang, Y. (2013) · Molecular Plant · doi:10.1093/mp/sst119 · Cited by 806 · see citing works

Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells

Kim, D., Kim, J., Hur, J. K., Been, K. W., Yoon, S.-H., & Kim, J.-S. (2016) · Nature Biotechnology · doi:10.1038/nbt.3609 · Cited by 731 · see citing works

Delivery technologies for genome editing

Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597 · see citing works

p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells

Tarangelo, A., Magtanong, L., Bieging-Rolett, K. T., Li, Y., Ye, J., Attardi, L. D., & Dixon, S. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.077 · Cited by 564 · see citing works

Germline mutations in RAD51D confer susceptibility to ovarian cancer

Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G. R., Kalmyrzaev, B., Warren-Perry, M., Snape, K. M. G., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 530 · see citing works

CRISPR/Cas system: recent advances and future prospects for genome editing

Manghwar, H., Lindsey, K., Zhang, X., & Jin, S. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.09.006 · Cited by 529 · cited 3× · see citing works

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Miliotou, Α. N., & Papadopoulou, L. C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180418095526 · Cited by 479 · see citing works

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478 · see citing works

Synthetic lethality as an engine for cancer drug target discovery

Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 470 · see citing works

CRISPR in cancer biology and therapy

Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00441-w · Cited by 440 · see citing works

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing

Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430 · see citing works

CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off‐Target Evaluation, and Strategies to Mitigate Off‐Target Effects

Manghwar, H., Li, B., Ding, X. L., Hussain, A., Lindsey, K., Zhang, X., & Jin, S. (2020) · Advanced Science · doi:10.1002/advs.201902312 · Cited by 394 · see citing works

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Xu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 391 · see citing works

Naturally Occurring Off-Switches for CRISPR-Cas9

Pawluk, A., Amrani, N., Zhang, Y., Garcı́a, B., Hidalgo-Reyes, Y., Lee, J., Edraki, A., Shah, M. K., Sontheimer, E. J., Maxwell, K. L., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.017 · Cited by 384 · see citing works

HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation

Li, Q. F., Ni, Y., Zhang, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00453-8 · Cited by 381 · see citing works

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

Mazur, P., Herner, A., Mello, S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 378 · see citing works

CRISPR/Cas: A powerful tool for gene function study and crop improvement

Zhang, D., Zhang, Z., Unver, T., & Zhang, B. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.10.003 · Cited by 373 · see citing works

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Dimitri, A. J., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 370 · see citing works

CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter

Choudhury, S. R., Cui, Y., Lubecka, K., Stefañska, B., & Irudayaraj, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10234 · Cited by 352 · see citing works

Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components

Kazemian, P., Yu, S.-Y., Thomson, S. B., Birkenshaw, A., Leavitt, B. R., & Ross, C. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00916 · Cited by 345 · see citing works

CRISPR/Cas9 for cancer research and therapy

Zhan, T., Rindtorff, N., Betge, J., Ebert, M., & Boutros, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 333 · see citing works

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 310 · see citing works

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 300 · see citing works

Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease

Kennedy, E. M., Kornepati, A. V. R., Goldstein, M., Bogerd, H. P., Poling, B. C., Whisnant, A. W., Kastan, M. B., & Cullen, B. R. (2014) · Journal of Virology · doi:10.1128/jvi.01879-14 · Cited by 296 · see citing works

Essential Features and Rational Design of CRISPR RNAs that Function with the Cas RAMP Module Complex to Cleave RNAs

Hale, C. R., Majumdar, S., Elmore, J. R., Pfister, N. T., Compton, M. M., Olson, S., Resch, A. M., Glover, C. V. C., Graveley, B. R., Terns, R. M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.10.023 · Cited by 294 · see citing works

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 282 · see citing works

Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice

Liu, P., Liang, S.-Q., Zheng, C., Mintzer, E., Zhao, Y. G., Ponnienselvan, K., Mir, A., Sontheimer, E. J., Gao, G., Flotte, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22295-w · Cited by 273 · see citing works

Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice

Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14716 · Cited by 271 · see citing works

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang, X., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00749-x · Cited by 267 · see citing works

Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges

Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259 · see citing works

Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01431-6 · Cited by 255 · see citing works

Quantitative profiling of initiating ribosomes in vivo

Gao, X., Wan, J., Liu, B., Ma, M., Shen, B., & Qian, S. (2014) · Nature Methods · doi:10.1038/nmeth.3208 · Cited by 238 · see citing works

Bioethical issues in genome editing by CRISPR-Cas9 technology

Ayanoğlu, F. B., ELÇİN, A. E., & Elçin, Y. M. (2020) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1912-52 · Cited by 233 · see citing works

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma

Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 232 · see citing works

Lysis of a Broad Range of Epithelial Tumour Cells by Human γδ T Cells: Involvement of NKG2D ligands and T‐cell Receptor‐ versus NKG2D‐dependent Recognition

Wrobel, P., Shojaei, H., Schittek, B., Gieseler, F., Wollenberg, B., Kalthoff, H., Kabelitz, D., & Wesch, D. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01963.x · Cited by 226 · see citing works

Transgenic Mouse Models in Cancer Research

Tratar, U. L., Horvat, S., & Čemažar, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00268 · Cited by 216 · see citing works

An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting

Cao, J. P., Wu, L., Zhang, S., Lu, M., Cheung, W. K. C., Cai, W. L., Gale, M., Xu, Q., & Yan, Q. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw660 · Cited by 216 · see citing works

Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing

Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 215 · see citing works

Enhancing CRISPR-Cas9 gRNA efficiency prediction by data integration and deep learning

Xiang, X., Corsi, G. I., Anthon, C., Qu, K., Pan, X., Liang, X., Han, P., Dong, Z., Liu, L., Zhong, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23576-0 · Cited by 209 · see citing works

Engineered materials for in vivo delivery of genome-editing machinery

Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 206 · see citing works

CRISPR–Act3.0 for highly efficient multiplexed gene activation in plants

Pan, C., Wu, X., Markel, K., Malzahn, A. A., Kundagrami, N., Sretenovic, S., Zhang, Y., Cheng, Y., Shih, P. M., & Qi, Y. (2021) · Nature Plants · doi:10.1038/s41477-021-00953-7 · Cited by 206 · see citing works

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

Ye, L., Park, J. J.-Y., Peng, L., Yang, Q., Chow, R. D.-W., Dong, M. B., Lam, S. Z., Guo, J., Tang, E., Zhang, Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.009 · Cited by 204 · see citing works

CRISPR: New Horizons in Phage Resistance and Strain Identification

Barrangou, R., & Horvath, P. (2012) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-022811-101134 · Cited by 198 · see citing works

Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing

Chen, X., Chen, Y., Xin, H., Wan, T. Y., & Yuan, P. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912220117 · Cited by 196 · see citing works

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice

Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 191 · see citing works

Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia

Ye, L., Wang, J., Tan, Y., Beyer, A. I., Xie, F., Muench, M. O., & Kan, Y. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612075113 · Cited by 190 · see citing works

Microglial IRF5-IRF4 regulatory axis regulates neuroinflammation after cerebral ischemia and impacts stroke outcomes

Mamun, A. A., Chauhan, A., Qi, S., Ngwa, C., Xu, Y., Sharmeen, R., Hazen, A. L., Li, J., Aronowski, J. A., McCullough, L. D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914742117 · Cited by 190 · see citing works

Rational designs of in vivo CRISPR-Cas delivery systems

Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 185 · see citing works

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183 · see citing works

Advances in CRISPR therapeutics

Chavez, M., Chen, X., Finn, P. B., & Qi, L. S. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00636-2 · Cited by 181 · see citing works

CRISPR–Cas: a tool for cancer research and therapeutics

Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 178 · see citing works

Survival of pancreatic cancer cells lacking KRAS function

Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · see citing works

In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161 · see citing works

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 160 · see citing works

Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34 + Hematopoietic Stem and Progenitor Cells

Chang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155 · see citing works

ALK in Neuroblastoma: Biological and Therapeutic Implications

Trigg, R. M., & Turner, S. D. (2018) · Cancers · doi:10.3390/cancers10040113 · Cited by 155 · see citing works

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Chen, L., Alexe, G., Dharia, N. V., Ross, L. S., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90793 · Cited by 151 · see citing works

The present and potential future methods for delivering CRISPR/Cas9 components in plants

Sandhya, D., Jogam, P., Allini, V. R., Abbagani, S., & Alok, A. (2020) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-020-00036-8 · Cited by 149 · see citing works

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 146 · see citing works

Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing

Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 143 · see citing works

Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core–Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy

Zhang, B.-C., Luo, B.-Y., Zou, J., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c17660 · Cited by 139 · see citing works

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment

Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J. Y., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 136 · see citing works

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 134 · see citing works

Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis

Anagnostou, T., Riaz, I. B., Hashmi, S. K., Murad, M. H., & Kenderian, S. S. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30277-5 · Cited by 131 · see citing works

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression

Koo, T., Yoon, A. R., Cho, H., Bae, S., Yun, C., & Kim, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx490 · Cited by 130 · see citing works

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Tsujino, T., Takai, T., Hinohara, K., Gui, F., Tsutsumi, T., Bai, X. F., Miao, C., Feng, C., Gui, B., Sztupinszki, Z. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35880-y · Cited by 130 · see citing works

A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing

Li, A., Lee, C. M., Hurley, A. E., Jarrett, K. E., Giorgi, M. D., Lu, W., Balderrama, K. S., Doerfler, A. M., Deshmukh, H., Ray, A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.009 · Cited by 129 · see citing works

ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition

Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 125 · see citing works

CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., Rao, T. N., & Sekar, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01565-1 · Cited by 122 · see citing works

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

Wang, G., Chow, R. D.-W., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 118 · see citing works

Simple and Efficient Targeting of Multiple Genes Through CRISPR-Cas9 in Physcomitrella patens

Lopez‐Obando, M., Hoffmann, B., Géry, C., Guyon‐Debast, A., Téoulé, E., Rameau, C., Bonhomme, S., & Nogué, F. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.033266 · Cited by 118 · see citing works

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Martínez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martín, M. C., Moya, F., Bustamante, O. Q., Garcı́a-Silva, S., Carcaboso, A. M., Petazzi, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18875-x · Cited by 118 · see citing works

Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids

Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 117 · see citing works

Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine

Sioson, V. A., Kim, M., & Joo, J. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00199-4 · Cited by 115 · see citing works

Engineered Cas9 extracellular vesicles as a novel gene editing tool

Osteikoetxea, X., da Silva, A. M., Lázaro‐Ibáñez, E., Salmond, N., Shatnyeva, O., Stein, J., Schick, J., Wren, S. A. C., Lindgren, J., Firth, M. A., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12225 · Cited by 114 · see citing works

Highly efficient genome editing via CRISPR–Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression

Li, X., Li, G., Fu, J. L., Fu, Y.-W., Zhang, L., Chen, W., Arakaki, C., Zhang, J., Wen, W., Zhao, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky804 · Cited by 113 · see citing works

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells

Zhou, X., Li, W., Wu, Y., Han, L., Cao, X., Yang, X.-M., Wang, H., Zhao, W., Zhai, W., Qi, Y., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02821 · Cited by 113 · see citing works

CRISPR-based therapeutics: current challenges and future applications

Modell, A. E., Lim, D., Nguyen, T. M., Sreekanth, V., & Choudhary, A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.012 · Cited by 112 · see citing works

Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice

Wilkinson, A. C., Dever, D. P., Baik, R., Camarena, J., Hsu, I., Charlesworth, C. T., Morita, C., Nakauchi, H., & Porteus, M. H. (2021) · Nature Communications · doi:10.1038/s41467-021-20909-x · Cited by 111 · see citing works

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

Walton, J. B., Farquharson, M., Mason, S. M., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D. J., Matzuk, M. M., Kim, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17119-1 · Cited by 110 · see citing works

Novel strategies to reverse chemoresistance in colorectal cancer

Ma, S., Zhang, J., Yan, T., Miao, M., Cao, Y., Cao, Y., Zhang, L., & Li, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5594 · Cited by 108 · see citing works

Enhanced mammalian genome editing by new Cas12a orthologs with optimized crRNA scaffolds

Teng, F., Li, J., Cui, T., Xu, K., Guo, L., Gao, Q., Feng, G., Chen, C., Han, D., Zhou, Q., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1620-8 · Cited by 105 · see citing works

Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles

Wan, F., Draz, M. S., Gu, M., Yu, W., Ruan, Z., & Luo, Q. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030352 · Cited by 103 · see citing works

Lipid nanoparticles loaded with ribonucleoprotein–oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition

Suzuki, Y., Onuma, H., Sato, R., Sato, Y., Hashiba, A., Maeki, M., Tokeshi, M., Kayesh, M. E. H., Kohara, M., Tsukiyama–Kohara, K., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.013 · Cited by 101 · see citing works

LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation

Zeng, K., Chen, X., Hu, X., Liu, X., Xu, T., Sun, H., Pan, Y., He, B., & Wang, S. (2018) · Oncogene · doi:10.1038/s41388-018-0352-7 · Cited by 101 · see citing works

CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

Jo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, J., Kim, J. H., Kim, J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 100 · see citing works

Development of CAR-T cell therapies for multiple myeloma

Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B., & Kröger, N. (2020) · Leukemia · doi:10.1038/s41375-020-0930-x · Cited by 99 · see citing works

CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment

Mollanoori, H., Shahraki, H., Rahmati, Y., & Teimourian, S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.09.007 · Cited by 99 · see citing works

Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia

Menendez-Gonzalez, J. B., Vukovic, M., Abdelfattah, A., Saleh, L., Almotiri, A., Thomas, L.-A., Lizaso, A. A., Azevedo, A., Menezes, A. C., Tornillo, G., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.07.005 · Cited by 97 · see citing works

Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing

Chen, Q., Zhang, Y., & Yin, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.014 · Cited by 96 · see citing works

A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression

Xi, L., Schmidt, J. C., Zaug, A. J., Ascarrunz, D., & Cech, T. R. (2015) · Genome biology · doi:10.1186/s13059-015-0791-1 · Cited by 95 · see citing works

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., Sturgeon, M. L., Kurgan, G., Amini, L., Stein, M., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.018 · Cited by 95 · see citing works

A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants

Kweon, J., Jang, A.-H., Shin, H. R., See, J.-E., Lee, W., Lee, J. W., Chang, S., Kim, K., & Kim, Y. (2019) · Oncogene · doi:10.1038/s41388-019-0968-2 · Cited by 92 · see citing works

Cx43 and Associated Cell Signaling Pathways Regulate Tunneling Nanotubes in Breast Cancer Cells

Tishchenko, A., Azorín, D., Vidal-Brime, L., Muñoz, M. J., Arenas, P. J., Pearce, C., Girão, H., Cajal, S., & Aasen, T. (2020) · Cancers · doi:10.3390/cancers12102798 · Cited by 92 · see citing works

Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system

García‐Bloj, B., Moses, C., Sgro, A., Plani-Lam, J. H. C., Arooj, M., Duffy, C., Thiruvengadam, S., Sorolla, A., Rashwan, R., Mancera, R. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11142 · Cited by 91 · see citing works

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Li, C., Mei, H., & Hu, Y. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz042 · Cited by 91 · see citing works

Wnt2 complements Wnt/β-catenin signaling in colorectal cancer

Jung, Y., Jun, S., Lee, S., Sharma, A., & Park, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6133 · Cited by 88 · see citing works

Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens

Awwad, S. W., Serrano-Benítez, A., Thomas, J. C., Gupta, V., & Jackson, S. P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00571-x · Cited by 87 · see citing works

Hallmarks of cancer: The CRISPR generation

Moses, C., García‐Bloj, B., Harvey, A. R., & Blancafort, P. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.002 · Cited by 87 · see citing works

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Pennesi, E., Michels, N., Brivio, E., van der Velden, V. H. J., Jiang, Y., Thano, A., Ammerlaan, A. C. J., Boer, J. M., Beverloo, H. B., Sleight, B., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01576-3 · Cited by 87 · see citing works

Transcription factor competition at the γ-globin promoters controls hemoglobin switching

Liu, N., Xu, S., Yao, Q., Zhu, Q., Yan, K., Hsu, J. Y., Sakon, P., Pinello, L., Yuan, G., Bauer, D. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00798-y · Cited by 86 · see citing works

PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations

Kolasa, I. K., Rembiszewska, A., Janiec–Jankowska, A., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.007 · Cited by 84 · see citing works

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

Gao, Q., Dong, X., Xu, Q., Zhu, L., Wang, F., Hou, Y., & Chao, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2257 · Cited by 81 · see citing works

Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation

Shen, C., Hsu, M., Chang, C.-W., Lin, M., Hwu, J. R., Tu, Y., & Hu, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1165 · Cited by 80 · see citing works

Magnetic microgels and nanogels: Physical mechanisms and biomedical applications

Sung, B., Kim, M., & Abelmann, L. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10190 · Cited by 80 · see citing works

Efficient combinatorial targeting of RNA transcripts in single cells with Cas13 RNA Perturb-seq

Wessels, H.-H., Méndez-Mancilla, A., Hao, Y., Papalexi, E., Mauck, W. M., Lu, L., Morris, J. A., Mimitou, E. P., Smibert, P., Sanjana, N. E., et al. (2023) · Nature Methods · doi:10.1038/s41592-022-01705-x · Cited by 79 · see citing works

Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

Fang, C., Xiao, G., Wang, T., Li, S., Peng, B., Xu, B., & Zhang, K. (2023) · Research · doi:10.34133/research.0108 · Cited by 79 · see citing works

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Chamberlain, C. A., Bennett, E., Kverneland, A. H., Svane, I. M., Donia, M., & Met, Ö. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.004 · Cited by 78 · see citing works

Development and application of CRISPR/Cas9 technologies in genomic editing

Zhang, C., Quan, R., & Wang, J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy120 · Cited by 77 · see citing works

CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer

Azangou‐Khyavy, M., Ghasemi, M., Khanali, J., Boroomand-Saboor, M., Jamalkhah, M., Soleimani, M., & Kiani, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02062 · Cited by 77 · see citing works

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Mo, F., Duan, S., Jiang, X., Yang, X., Hou, X., Shi, W., Jumbo, J. C. C., Liu, A., Yin, S., Wang, W., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00462-1 · Cited by 77 · see citing works

Nanomedicine-based cancer immunotherapy: recent trends and future perspectives

Lakshmanan, V., Jindal, S., Packirisamy, G., Ojha, S. K., Lian, S., Kaushik, A. K., Alzarooni, A. I. M. A., Metwally, Y. H. H., Thyagarajan, S. P., Jung, Y. D., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00299-4 · Cited by 76 · see citing works

Genome Editing and Its Applications in Model Organisms

Ma, D., & Liu, F. (2015) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.12.001 · Cited by 76 · see citing works

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment

Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein‐Bey‐Abina, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830292 · Cited by 75 · see citing works

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.

Koh, S., Kah, J., Tham, C. Y. L., Yang, N., Ceccarello, E., Chia, A., Chen, M., Khakpoor, A., Pavesi, A., Tan, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.027 · Cited by 74 · see citing works

CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods

Rayner, E., Durin, M.-A., Thomas, R. J., Moralli, D., O'Cathail, S. M., Tomlinson, I. P. M., Green, C., & Lewis, A. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0006 · Cited by 73 · see citing works

CRISPR/Cas9-The ultimate weapon to battle infectious diseases?

Doerflinger, M., Forsyth, W. O., Ebert, G., Pellegrini, M., & Herold, M. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12693 · Cited by 72 · see citing works

CD58 loss in tumor cells confers functional impairment of CAR T cells

Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007891 · Cited by 72 · see citing works

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

Annunziato, S., de Ruiter, J. R., Henneman, L., Brambillasca, C. S., Lutz, C., Vaillant, F., Ferrante, F., Drenth, A. P., van der Burg, E., Siteur, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08301-2 · Cited by 69 · see citing works

Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment

Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 69 · see citing works

Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes

Zhen, S., Liu, Y., Lu, J., Tuo, X., Yang, X., Chen, H., Chen, W., & Li, X. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.312 · Cited by 66 · see citing works

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?

Mirgayazova, R., Khadiullina, R., Chasov, V. V., Mingaleeva, R. N., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2020) · Genes · doi:10.3390/genes11060704 · Cited by 66 · see citing works

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

Rahman, S., Magnussen, M., León, T., Farah, N., Li, Z.-D., Alapi, K., Mitchell, R., Naughton, T., Fielding, A., Pizzey, A., et al. (2016) · Blood · doi:10.1182/blood-2016-09-742148 · Cited by 64 · see citing works

Precise tuning of gene expression levels in mammalian cells

Michaels, Y. S., Barnkob, M. B., Barbosa, H., Baeumler, T. A., Thompson, M. K., André, V., Colin‐York, H., Fritzsche, M., Gileadi, U., Sheppard, H. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08777-y · Cited by 64 · see citing works

Silencing of miR-138-5p sensitizes bone anabolic action to mechanical stimuli

Chen, Z., Zhao, F., Liang, C., Hu, L., Li, D., Zhang, Y., Yin, C., Chen, L., Wang, L., Lin, X., et al. (2020) · Theranostics · doi:10.7150/thno.53009 · Cited by 63 · see citing works

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan

Maitra, R., Seetharam, R. N., Tesfa, L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1921 · Cited by 62 · see citing works

Spatial and Temporal Control of CRISPR-Cas9-Mediated Gene Editing Delivered via a Light-Triggered Liposome System

Aksoy, Y. A., Yang, B., Chen, W., Hung, T., Kuchel, R. P., Zammit, N. W., Grey, S. T., Goldys, E. M., & Deng, W. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16380 · Cited by 62 · see citing works

A phase 1 trial of NY‐ESO ‐1‐specific TCR ‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

Ishihara, M., Nishida, Y., Kitano, S., Kawai, A., Muraoka, D., Momose, F., Harada, N., Miyahara, Y., Seo, N., Hattori, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34453 · Cited by 61 · see citing works

Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?

Blackburn, A. C., & Jerry, D. J. (2002) · Breast Cancer Research · doi:10.1186/bcr427 · Cited by 60 · see citing works

A Chimeric Egfr Protein Reporter Mouse Reveals Egfr Localization and Trafficking In Vivo

Yang, Y.-P., Ma, H., Starchenko, A., Huh, W. J., Li, W., Hickman, F. E., Zhang, Q., Franklin, J. L., Mortlock, D. P., Fuhrmann, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.048 · Cited by 60 · see citing works

Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer

Jiang, C., Lin, X., & Zhao, Z. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.007 · Cited by 60 · see citing works

Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV

Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Sezgin, Y., Devine, R. D., Lyberger, J. M., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100236 · Cited by 59 · see citing works

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Jung, S., Kim, D. H., Choi, Y. J., Kim, S. Y., Park, H., Lee, H., Choi, C., Sung, Y. H., Lee, J. C., & Rho, J. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-99267-z · Cited by 56 · see citing works

FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma

Liu, J.-L., Guzmán, M. A., Pezanowski, D. M., Patel, D. M., Hauptman, J. E., Keisling, M., Hou, S. J., Papenhausen, P., Pascasio, J., Punnett, H., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.98 · Cited by 56 · see citing works

CRISPR/Cas mediated epigenome editing for cancer therapy

Ansari, I., Chaturvedi, A., Chitkara, D., & Singh, S. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.018 · Cited by 56 · see citing works

The interplay of CDK4 and CDK6 in melanoma

Kollmann, K., Briand, C., Bellutti, F., Schicher, N., Blunder, S., Zojer, M., & Höeller, C. (2019) · Oncotarget · doi:10.18632/oncotarget.26515 · Cited by 55 · see citing works

CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway

Zhang, S., Zhang, F., Chen, Q., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1462-y · Cited by 54 · see citing works

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines

Lentsch, E., Li, L., Pfeffer, S., Ekici, A. B., Taher, L., Pilarsky, C. P., & Grützmann, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225706 · Cited by 54 · see citing works

Inhalation delivery technology for genome-editing of respiratory diseases

Chow, M. Y. T., Chang, R. Y. K., & Chan, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.001 · Cited by 54 · see citing works

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells

Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30205-2 · Cited by 53 · see citing works

Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families

Osher, D. J., Leeneer, K. D., Michils, G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.87 · Cited by 52 · see citing works

Delivery systems of CRISPR/Cas9-based cancer gene therapy

Biagioni, A., Laurenzana, A., Margheri, F., Chillà, A., Fibbi, G., & Rosso, M. D. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0127-2 · Cited by 52 · see citing works

Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance

Bowden, A. R., Morales-Juarez, D. A., Sczaniecka-Clift, M., Agudo, M. M., Lukashchuk, N., Thomas, J. C., & Jackson, S. P. (2020) · eLife · doi:10.7554/elife.55325 · Cited by 52 · see citing works

Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease, and Regenerative Medicine

Adigbli, G., Ménoret, S., Cross, A. R., Hester, J., Issa, F., & Anegón, I. (2020) · Transplantation · doi:10.1097/tp.0000000000003177 · Cited by 51 · see citing works

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

Mintz, R. L., Lao, Y., Chi, C., He, S., Li, M., Quek, C. H., Shao, D., Chen, B., Han, J., Wang, S., et al. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10152 · Cited by 50 · see citing works

Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice

Xu, L. M., Lau, Y. S., Gao, Y., Bailin, P. L., & Han, R. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.001 · Cited by 50 · see citing works

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Vesga, C. P. C., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2519 · Cited by 49 · see citing works

Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages

Navarro‐Guerrero, E., Tay, C., Whalley, J. P., Cowley, S. A., Davies, B., Knight, J. C., & Ebner, D. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-82137-z · Cited by 47 · see citing works

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Zhang, Z., Kong, X., Ligtenberg, M. A., Veen, S. E. V. H.-V., Visser, N. L., de Bruijn, B., Stecker, K. E., van der Helm, P. W., Kuilman, T., Hoefsmit, E. P., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100655 · Cited by 47 · see citing works

Toward Gene Transfer Nanoparticles as Therapeutics

Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 46 · see citing works

Interleukin-7 and Interleukin-15 for Cancer

Zarogoulidis, P., Lampaki, S., Yarmus, L. B., Kioumis, I. P., Pitsiou, G., Katsikogiannis, N., Hohenforst‐Schmidt, W., Li, Q., Huang, H., Sakkas, A., et al. (2014) · Journal of Cancer · doi:10.7150/jca.10471 · Cited by 46 · see citing works

Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer

Zhen, S., & Li, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486168 · Cited by 46 · see citing works

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring <i>RAS</i> Mutations

Yamada, T., Amann, J. M., Tanimoto, A., Taniguchi, H., Shukuya, T., Timmers, C., Yano, S., Shilo, K., & Carbone, D. P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0146 · Cited by 44 · see citing works

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Kießling, M. K., Schuierer, S., Stertz, S., Beibel, M., Bergling, S., Knehr, J., Carbone, W., de Vallière, C., Tchinda, J., Bouwmeester, T., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-3042-2 · Cited by 44 · see citing works

MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research

Chen, X., Li, X., Wang, X., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5371-4 · Cited by 44 · see citing works

A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy

Gao, J., Luo, T., Lin, N., Zhang, S., & Wang, J. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.09.004 · Cited by 44 · see citing works

AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway

Liang, S., Walkey, C. J., Martinez, A. E., Su, Q., Dickinson, M. E., Wang, D., Lagor, W. R., Heaney, J. D., Gao, G., & Xue, W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.023 · Cited by 44 · see citing works

Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges

Rafii, S., Tashkandi, E. M., Bukhari, N., & Al-Shamsi, H. O. (2022) · Cancers · doi:10.3390/cancers14040947 · Cited by 44 · see citing works

Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy

Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 43 · see citing works

Light-responsive charge-reversal nanovector for high-efficiency in vivo CRISPR/Cas9 gene editing with controllable location and time

Wu, Y., Zheng, J., Zeng, Q., Zhang, T., & Xing, D. (2020) · Nano Research · doi:10.1007/s12274-020-2864-z · Cited by 43 · see citing works

Translating CRISPR-Cas Therapeutics: Approaches and Challenges

Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 43 · see citing works

Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing

Bonafont, J., Mencía, Á., Chacón-Solano, E., Srifa, W., Vaidyanathan, S., Romano, R., García, M., Hervás-Salcedo, R., Ugalde, L., Duarte, B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.019 · Cited by 43 · see citing works

Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System

Getahun, Y. A., Ali, D. A., Taye, B. W., & Alemayehu, Y. A. (2022) · Veterinary Medicine Research and Reports · doi:10.2147/vmrr.s366533 · Cited by 43 · see citing works

NFκB regulates p21 expression and controls DNA damage-induced leukemic differentiation

Nicolae, C. M., O’Connor, M. J., Constantin, D., & Moldovan, G. (2018) · Oncogene · doi:10.1038/s41388-018-0219-y · Cited by 42 · see citing works

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

Castells‐Roca, L., Tejero, E., Rodríguez‐Santiago, B., & Surrallés, J. (2021) · Cancers · doi:10.3390/cancers13071591 · Cited by 42 · see citing works

Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes

Fine, E. J., Appleton, C. M., White, D. E., Brown, M. T., Deshmukh, H., Kemp, M. L., & Bao, G. (2015) · Scientific Reports · doi:10.1038/srep10777 · Cited by 41 · see citing works

CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells

Kamali, E., Rahbarizadeh, F., Hojati, Z., & Frödin, M. (2021) · BMC Biotechnology · doi:10.1186/s12896-020-00665-4 · Cited by 40 · see citing works

Review of applications of CRISPR-Cas9 gene-editing technology in cancer research

Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00151-x · Cited by 40 · see citing works

Structure of a type IV CRISPR-Cas ribonucleoprotein complex

Zhou, Y., Bravo, J. P. K., Taylor, H. N., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102201 · Cited by 39 · see citing works

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 39 · see citing works

Dual-Responsive Core–Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy

Liu, J., Li, G., Guo, H., Ni, C., Gao, Y., Cao, X., Xia, J., Shi, X., & Guo, R. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c22584 · Cited by 39 · see citing works

Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Li, C., Ding, L., Sun, C., Wu, L.-C., Zhou, D., Pawlik, K. M., Khodadadi‐Jamayran, A., Westin, E. R., Goldman, F. D., & Townes, T. M. (2016) · Scientific Reports · doi:10.1038/srep30422 · Cited by 38 · see citing works

CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy

Huang, D., Miller, M., Ashok, B., Jain, S., & Peppas, N. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.015 · Cited by 38 · see citing works

Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease

Hartmann, O., Reissland, M., Maier, C. R., Fischer, T., Prieto‐Garcia, C., Baluapuri, A., Schwarz, J. D., Schmitz, W., Garrido‐Rodríguez, M., Pahor, N., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641618 · Cited by 38 · see citing works

RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches

Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10 · see citing works

Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells

Hunt, J., Samson, C., du Rand, A., & Sheppard, H. M. (2023) · Human Genetics · doi:10.1007/s00439-023-02561-1 · Cited by 125 · see citing works

Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity

Wang, Y., Wang, H., Jian, Y.-Z., Luo, Z., Shao, H., & Zhang, W. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.283 · Cited by 3 · see citing works

Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review

Ebrahimi, V., & Hashemi, A. (2020) · Gene · doi:10.1016/j.gene.2020.144813 · Cited by 32 · see citing works

CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases

Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 18 · see citing works

CRISPR–Cas9 gene editing induced complex on-target outcomes in human cells

Wen, W., & Zhang, X. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.002 · Cited by 38 · see citing works